Updated Treatment of Non‐Steroidal Anti‐Inflammatory Drug‐Exacerbated Respiratory Disease: How to Decide on Aspirin Therapy After Desensitization or Biologics? When? How? An EAACI Task Force Report
Allergy · 2026
DOI: 10.1111/all.70243 ↗At a glance
Übersichtsarbeit in Allergy, 2026. Written by Gülfem E Çelik and 13 co-authors. Institution: Department of Chest Disease, Division of Immunology and Allergy, Ankara University School of Medicine, and Private Practice, Ankara, Türkiye. Major MEDLINE topics: Anti-Inflammatory Agents, Non-Steroidal, Desensitization, Immunologic, Aspirin, Biological Products. Cited 4 times so far (Crossref); 122 references. The full text is freely available in PubMed Central. Funded by: European Academy of Allergy and Clinical Immunology.
Abstract (original language)
Nonsteroidal anti‐inflammatory drug (NSAID)‐exacerbated respiratory disease (NSAID‐ERD) is a heterogeneous condition characterized by chronic eosinophilic airway inflammation in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma whose symptoms are aggravated after ingestion of aspirin and other NSAIDs. As a unique treatment, aspirin treatment after desensitization (ATAD) has been in use for several years after showing the inhibitory effect on CRS symptoms and nasal polyp growth as well as severe asthma. However, in recent years, biologics have also shown to cause a decrease in polyp size as well as associated outcomes such as quality of life. In this manuscript, considerations on choosing the best treatment of NSAID–ERD are laid out based on current literature.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Chest Disease, Division of Immunology and Allergy, Ankara University School of Medicine, and Private Practice, Ankara, Türkiye.
- Department of Rheumatology and Clinical Immunology, Medical University of Lodz, Lodz, Poland.
- Allergy Research Group, IBIMA Plataforma BIONAND, Málaga, Spain.
- Departamento de Medicina, Universidad de Málaga-UMA, Málaga, Spain.
- Allergy Unit, Hospital Regional Universitario de Málaga and IBIMA Plataforma BIONAND, Málaga, Spain.
- RICORS Red De Enfermedades Inflamatorias (REI), Madrid, Spain.
ORCID profiles: Gülfem E Çelik, Joanna S Makowska, Maria Jose Torres, Cristobalina Mayorga, Tanya M Laidlaw, Sanna Toppila-Salmi, Ludger Klimek, Aslı Gelincik, Annick Barbaud, Lene H Garvey, Ömür Aydın, Thomas Eiwegger, Katharine M Woessner
Funding
- European Academy of Allergy and Clinical Immunology
Cite
APA
Çelik, G. E., Makowska, J. S., Torres, M. J., Mayorga, C., Laidlaw, T. M., Vultaggio, A., Toppila-Salmi, S., Klimek, L., Gelincik, A., Barbaud, A., Garvey, L. H., Aydın, Ö., Eiwegger, T., & Woessner, K. M. (2026). Updated Treatment of Non‐Steroidal Anti‐Inflammatory Drug‐Exacerbated Respiratory Disease: How to Decide on Aspirin Therapy After Desensitization or Biologics? When? How? An EAACI Task Force Report. Allergy. https://doi.org/10.1111/all.70243
Vancouver
Çelik GE, Makowska JS, Torres MJ, Mayorga C, Laidlaw TM, Vultaggio A, et al. Updated Treatment of Non‐Steroidal Anti‐Inflammatory Drug‐Exacerbated Respiratory Disease: How to Decide on Aspirin Therapy After Desensitization or Biologics? When? How? An EAACI Task Force Report. Allergy. 2026. doi:10.1111/all.70243
BibTeX
@article{elik2026,
author = {Çelik, Gülfem E and Makowska, Joanna S and Torres, Maria Jose and Mayorga, Cristobalina and Laidlaw, Tanya M and Vultaggio, Alessandra and Toppila-Salmi, Sanna and Klimek, Ludger and Gelincik, Aslı and Barbaud, Annick and Garvey, Lene H and Aydın, Ömür and Eiwegger, Thomas and Woessner, Katharine M},
title = {Updated Treatment of Non‐Steroidal Anti‐Inflammatory Drug‐Exacerbated Respiratory Disease: How to Decide on Aspirin Therapy After Desensitization or Biologics? When? How? An EAACI Task Force Report},
journal = {Allergy},
year = {2026},
doi = {10.1111/all.70243}
}
EUVIMED